Ubs Oconnor LLC C4 Therapeutics, Inc. Transaction History
Ubs Oconnor LLC
- $1.46 Billion
- Q3 2024
A detailed history of Ubs Oconnor LLC transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Ubs Oconnor LLC holds 23,000 shares of CCCC stock, worth $83,950. This represents 0.01% of its overall portfolio holdings.
Number of Shares
23,000Holding current value
$83,950% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding CCCC
# of Institutions
126Shares Held
63.5MCall Options Held
670KPut Options Held
54.8K-
Lynx1 Capital Management LP San Juan, PR6.88MShares$25.1 Million14.04% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT6.6MShares$24.1 Million3.2% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT5.68MShares$20.7 Million0.16% of portfolio
-
Ra Capital Management, L.P. Boston, MA4.88MShares$17.8 Million0.39% of portfolio
-
Black Rock Inc. New York, NY4.55MShares$16.6 Million0.0% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $179M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...